Alexandra Tyulyandina

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Christian Marth, R. Tarnawski, Alexandra Tyulyandina et al. · International Journal of Gynecological Cancer · 2021 · 66 citations · Full text

Medicine, Oncology, Pharmacology +15

Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies

Alexandra Tyulyandina, Daniel Harrison, Wei Yin et al. · Investigational New Drugs · 2016 · 24 citations

Medicine, Oncology, Pharmacology +14

KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.

Brian M. Slomovitz, David Cibula, Tayup Şimşek et al. · Journal of Clinical Oncology · 2022 · 23 citations

Medicine, Oncology, Pharmacology +16

HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?

Yu Yu Andreeva, Alexey I. Kalinkin, T. E. Tikhomirova et al. · International Journal of Molecular Sciences · 2023 · 21 citations · Full text

Life Sciences, Genetics, Oncology +13